NASDAQ · MLYS
Mineralys Therapeutics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for MLYS: Nov 04, 2026
Mineralys Therapeutics, Inc. Common Stock is expected to report earnings on 11/04/2026 after market close. The report will be for the fiscal Quarter ending Sep 2026. According to Zacks Investment Research, based on 4 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.53. The reported EPS for the same quarter last year was $-0.52.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.53 | $-0.45 | $-0.60 | 4 |
| Dec 2026 | $-0.60 | $-0.55 | $-0.68 | 3 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Fintel · RTTNews · The Motley Fool · MarketBeat- Fintel · 10 h agoMineralys Therapeutics, Inc. Terminates License Agreement and Acquires Lorundrostat IP from Tanabe PharmaOn October 27, 2026, Mineralys Therapeutics, Inc. and Tanabe Pharma Corporation entered into a Termination Agreement, pursuant to which the parties terminated their License Agreement, dated July 9, 2020 and amended on November 24, 2020, June 15, 2023, May 29, 2025 and June 2, 202
- RTTNews · Oct 28, 9:42 AM EDTMineralys Reports Phase 2 Lorundrostat Data In Chronic Kidney Disease(RTTNews) – Mineralys Therapeutics Inc. (MLYS) announced that full results from its Phase 2 Explore-CKD trial of investigational Lorundrostat have been published in Kidney International. The study evaluated the drug in patients with uncontrolled high blood pressure and chronic ki
- The Motley Fool · Aug 18, 7:13 PM EDTMineralys (MLYS) Q2 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- MarketBeat · Aug 11, 7:04 PM EDTMineralys Therapeutics Q2 Earnings Call HighlightsThere's a Lot to Love About Mineralys' Valentine's Day IPO Mineralys Therapeutics (NASDAQ:MLYS) said it is continuing commercial-launch preparations for lorundrostat ahead of its December 22 Prescription Drug User Fee Act target date, while reporting a wider second-quarter loss d
- NASDAQ.com · Aug 11, 2:00 PM EDTAfter-Hours Earnings Report for August 11, 2026 : LITE, FNV, CRWV, SMCI, CAVA, IFS, HRB, FLY, MLYS, NN, TGLS, TSHAThe following companies are expected to report earnings after hours on 08/11/2026. Visit our Earnings Calendar for a full list of expected earnings releases.Lumentum Holdings Inc. (LITE)is reporting for the quarter ending June 30, 2026. The communications company's consensus ear
- The Motley Fool · Jul 16, 5:05 PM EDTA Mineralys Insider Banked a $557,000 Options Gain Before a December FDA DateThe executive sold 20,407 shares at a weighted average price of $27.28 per share, totaling approximately $557,000 in gross proceeds.
- The Motley Fool · Jul 16, 4:57 PM EDTWhat to Know About This Mineralys Insider Sale Before a December FDA DateThe CEO of Mineralys reported selling 10,700 shares for $291,468 on July 13, 2026.
- The Motley Fool · Jun 23, 5:39 PM EDTWhat a $350,000 Insider Sale Might Mean for Mineralys Ahead of December FDA DecisionThe Chief Medical Officer of Mineralys Therapeutics reported selling 14,474 Common Stock shares across multiple transactions on June 15 and June 17, 2026, for a total value of approximately $350,000.
- RTTNews · Jun 15, 5:26 AM EDTMineralys Reports Lorundrostat Reduced Heart Failure Risk Biomarkers In Hypertension Trials(RTTNews) – Mineralys Therapeutics, Inc. (MLYS), reported positive post hoc data from Phase 3 Launch-HTN and Phase 2b Advance-HTN trials on the effect of Lorundrostat on heart failure risk biomarkers.
- The Motley Fool · May 31, 10:39 AM EDTVelan Capital Drops 140,000 Mineralys Therapeutics (MLYS) Shares Worth $4.1 MillionReduced stake by 140,000 shares; estimated transaction value of $4.11 million based on quarterly average price
- The Motley Fool · May 6, 6:38 PM EDTMineralys (MLYS) Q1 2026 Earnings Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- Fintel · Apr 27, 8:04 PM EDTTD Cowen Initiates Coverage of Mineralys Therapeutics (MLYS) with Buy RecommendationFintel reports that on April 27, 2026, TD Cowen initiated coverage of Mineralys Therapeutics (NasdaqGS:MLYS) with a Buy recommendation. Analyst Price Forecast Suggests 86.74% Upside
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Mineralys Therapeutics, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.